Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL602566 | 0.92 | TP53 (0.41) | — | |
| SCHEMBL4812030 | 0.84 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL3224166 | 0.84 | TSHR (0.39) | TSHRALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6130624 | 0.80 | ZDHHC20 (0.36) | TSHRALDH1A1 | |
| SCHEMBL7159683 | 0.79 | TSHR (0.31) | TSHR | |
| SCHEMBL12254047 | 0.79 | TYMP (0.33) | ALDH1A1 | |
| SCHEMBL28142568 | 0.79 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL990607 | 0.79 | TSHR (0.31) | TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL28669748 | 0.79 | TSHR (0.31) | TSHR | |
| SCHEMBL27900997 | 0.79 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299561-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | NEKTAR THERAPEUTICS | 2024-09-12 | — | — | US | claimed |
| EP-4355371-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | Nektar Therapeutics (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2022266498-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | NEKTAR THERAPEUTICS (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220332867-A1 | HYDROXYALKYLAMIDE FUNCTIONALIZED ACRYLIC POLYMERS AND PROCESS FOR MANUFACTURING THEM | POLIRESIN S R L (IT) | 2022-10-20 | — | — | US | claimed |
| EP-4025617-A1 | HYDROXYALKYLAMIDE FUNCTIONALIZED ACRYLIC POLYMERS AND PROCESS FOR MANUFACTURING THEM | Poliresin S.r.l. (IT) | 2022-07-13 | — | — | EP | claimed |
| CN-110023365-B | Use of acrylates and acrylamides for reducing emissions from polyurethane foams | 科思创德国股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20210139634-A1 | USE OF ACRYLIC ACID ESTERS AND AMIDES FOR REDUCING EMISSIONS OF A POLYURETHANE FOAM | COVESTRO DEUTSCHLAND AG (DE) | 2021-05-13 | — | — | US | claimed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | claimed |
| EP-3452120-B1 | MACROSCOPICALLY ALIGNABLE, INJECTABLE, SOFT HYDROGEL COMPOSITION | DWI LEIBNIZ INSTITUT FUER INTERAKTIVE MAT E V (DE) | 2020-05-27 | — | — | EP | claimed |
| US-20200079923-A1 | USE OF ACRYLIC ACID ESTERS AND AMIDES FOR REDUCING EMISSIONS OF A POLYURETHANE FOAM | COVESTRO DEUTSCHLAND AG (DE) | 2020-03-12 | — | — | US | claimed |
| CN-102973488-A | Nano-hydrogel with oxidation-reduction/pH double-stimulation responsiveness and preparation method and application thereof | UNIV FUDAN | 2013-03-20 | — | — | CN | claimed |
| CN-102421452-A | Multivalent adjuvant display | HYBRID BIOSYSTEMS LTD | 2012-04-18 | — | — | CN | claimed |
| US-7425581-B2 | Temperature sensitive polymers | UNIVERSITEIT UTRECHT | 2008-09-16 | — | — | US | claimed |
| EP-1545637-B1 | ENZYME-SENSITIVE THERAPEUTIC WOUND DRESSINGS | JOHNSON & JOHNSON MEDICAL LTD (GB) | 2006-08-02 | — | — | EP | claimed |
| US-20060140909-A1 | Method of using adenoviral vectors with increased persistence in vivo | GENVEC, INC. (US) | 2006-06-29 | — | — | US | claimed |
| WO-2005117993-A2 | METHOD OF USING ADENOVIRAL VECTORS WITH IMPROVED SAFETY AND EFFICACY FOR THE TREATMENT OF CANCER | GENVEC, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| EP-1597377-A2 | METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED PERSISTENCE IN VIVO | GENVEC, INC. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004076627-A2 | METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED PERSISTENCE IN VIVO | GENVEC INC. (US) | 2004-09-10 | — | — | WO | claimed |
| US-20040167088-A1 | Method of using adenoviral vectors with increased persistence in vivo | GENVEC, INC. | 2004-08-26 | — | — | US | claimed |
| CN-1443079-A | Polymeric conjugates of antitumor agents | PHARMACIA ITALIA SPA (IT) | 2003-09-17 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | TSHR 338/4885ALDH1A1 1750/4885CHRNB2 3958/4885 |
| US-20240299561-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | HNMT, PHYKPL, PHPT1 | TSHR 1481/4885ALDH1A1 4067/4885CHRNB2 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.